Novavax (NASDAQ:NVAX) Price Target Raised to $17.00 at HC Wainwright

Novavax (NASDAQ:NVAX) had its price objective upped by HC Wainwright from $10.00 to $17.00 in a research note released on Wednesday, Briefing.com Automated Import reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also recently commented on NVAX. ValuEngine raised shares of Novavax from a sell rating to a hold rating in a research note on Thursday, August 1st. Cantor Fitzgerald reissued a hold rating on shares of Novavax in a research note on Thursday, May 9th. Zacks Investment Research raised shares of Novavax from a hold rating to a buy rating and set a $8.00 price target on the stock in a research note on Thursday, May 16th. Chardan Capital reaffirmed a neutral rating and issued a $7.00 price objective on shares of Novavax in a research note on Friday, May 10th. Finally, Oppenheimer lifted their price target on shares of Novavax from $1.25 to $25.00 in a research report on Monday, May 13th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company. Novavax presently has a consensus rating of Hold and an average target price of $40.70.

NVAX opened at $7.84 on Wednesday. Novavax has a one year low of $4.01 and a one year high of $51.60. The company’s 50 day simple moving average is $4.82 and its 200-day simple moving average is $3.17.

Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.61) by ($0.08). The firm had revenue of $3.36 million for the quarter, compared to analyst estimates of $3.53 million. During the same quarter in the prior year, the business earned ($2.40) earnings per share. As a group, equities analysts anticipate that Novavax will post -5.6 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Amalgamated Bank raised its holdings in shares of Novavax by 32.0% during the fourth quarter. Amalgamated Bank now owns 54,361 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 13,171 shares during the period. Legal & General Group Plc raised its holdings in shares of Novavax by 30.9% during the fourth quarter. Legal & General Group Plc now owns 74,389 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 17,575 shares during the period. DekaBank Deutsche Girozentrale raised its holdings in shares of Novavax by 21.8% during the first quarter. DekaBank Deutsche Girozentrale now owns 123,100 shares of the biopharmaceutical company’s stock worth $185,000 after acquiring an additional 22,000 shares during the period. Wedbush Securities Inc. raised its holdings in shares of Novavax by 102.1% during the first quarter. Wedbush Securities Inc. now owns 54,444 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 27,500 shares during the period. Finally, GSA Capital Partners LLP acquired a new stake in shares of Novavax during the second quarter worth $197,000.

About Novavax

Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.

Featured Article: Why is the ex-dividend date different from the record date?

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.